Article Text

other Versions

Download PDFPDF
The monoclonal anti-CD25 antibody basiliximab for the treatment of progressive systemic sclerosis: an open-label study
  1. M O Becker1,
  2. C Brückner1,
  3. H U Scherer1,
  4. N Wassermann1,
  5. J Y Humrich1,
  6. L G Hanitsch2,
  7. U Schneider1,
  8. A Kawald1,
  9. K Hanke1,
  10. G R Burmester1,
  11. G Riemekasten1
  1. 1Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany
  2. 2Department of Infectious Diseases and Pulmonology, Charité Universitätsmedizin Berlin, Berlin, Germany
  1. Correspondence to Professor Dr Gabriela Riemekasten, C12, CCM, Department of Rheumatology and Clinical Immunology, Charitéplatz 1, 10117 Berlin, Germany; Gabriela.Riemekasten{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Systemic sclerosis (SSc) is characterised by skin fibrosis together with a dysfunction of the immune system and vasculopathy. Until now, only a few accepted treatment options have existed for patients with progressive disease.1 A similar skin fibrosis is seen in graft-versus-host disease, an immunologically mediated disease in recipients of haematological stem cells.2 In graft-versus-host disease, targeting of CD25-positive lymphocytes with a monoclonal antibody (basiliximab) has been shown to reduce its syptoms and complications.3 CD25 is the cluster designation for the high-affinity interleukin-2 receptor expressed on T and B lymphocytes after their activation. Activated lymphocytes are also thought to play a role in the pathogenesis of SSc as patients have elevated serum interleukin-2 receptor levels and the levels correlate with mortality and disease duration.4 5 As we had already treated one rapidly progressive SSc patient refractory to other forms of treatment with the monoclonal antibody basiliximab,6 we started a …

View Full Text


  • Funding The study was partly financially supported by a grant from Novartis, Germany.

  • Competing interests None.

  • Patient consent Obtained.

  • Ethics approval This study was conducted with the approval of the local ethics committee.

  • Provenance and peer review Not commissioned; externally peer reviewed.